Analysts Expect Antibiotics Market to Slide

Datamonitor says in a new report that Big Pharma is shunning the development of oral antibiotic blockbusters as it stays focused on next-gen IV treatments to fight off MRSA and other superbug infections which afflict hospitalized patients.

With few new product launches in the works and generic competition growing, the analysts at Datamonitor expect to see revenue in the field slide from $19.6 billion in 2009 to about $16.4 billion in 2019, according to an AP report. Two years ago there were three antibiotic blockbusters on the mark